NASDAQ OMX

New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria

Dela

Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options

CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) -- As the global community gathers for World Malaria Day to celebrate successes and plot strategy to eliminate the disease from the face of the earth, a new ray of hope is emerging from a surprising place: the testing side of the equation.

Meridian Bioscience, Inc. of Cincinnati, Ohio (NASDAQ:VIVO) has developed  illumi gene® Malaria, a molecular-based, field laboratory-deployed test for malaria that is up to 80,000 times more sensitive at detecting the malaria parasite than current testing options. The test was developed by Meridian with the technical assistance of the Centers for Disease Control and Prevention (CDC) and Cheikh Anta Diop University of Dakar, Senegal. 

" illumi gene Malaria has the potential to change current practices. Faster and more accurate diagnosis is vital in the fight against malaria," said Professor Daouda Ndiaye, Department of Parasitology-Mycology, Cheikh Anta Diop University. "Earlier diagnosis enables the correct treatment to be prescribed, which leads to better clinical outcomes for the person with malaria and keeps malaria treatments for the right people. And because detecting the malaria parasite in people with a low parasite count has proven difficult, a robust, sensitive and field laboratory-deployable diagnostic tool is needed to track the malaria reservoir in pre-elimination regions.  illumi gene Malaria shows this capacity."

illumi gene Malaria was awarded first place for innovation in emergency treatment and point-of-care testing at the prestigious Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes Conference in Paris, and is CE marked for sale in Europe.

Despite a 60% decline in malaria deaths since 2000 due to better prevention and increased control measures, malaria is still one of the top three killers of children worldwide, claiming one life every minute of every day. (1) According to the latest data from the World Health Organization, nearly half of the world's population is at risk of malaria (2). In 2015, there were roughly 212 million malaria cases and an estimated 429,000 malaria deaths (3). Also that year, Sub-Saharan Africa was home to 90% of malaria cases and 92% of malaria deaths (4). More than two-thirds (70%) of all malaria deaths occur in children under the age of five (5).

While malaria is preventable and treatable (6), proper diagnosis is critical. Molecular testing has proven to be more effective than current options in detecting the malaria parasite at very low levels, known as "loads." Identifying low-load individuals has the dual benefit of ensuring they receive treatment and preventing the spread of the disease to others.

"People can be carriers of malaria without showing any symptoms, and detecting these asymptomatic individuals can be challenging," said Slava Elagin, Executive Vice President, Research & Development at Meridian Bioscience. "If testing doesn't identify them, eliminating malaria is impossible because these individuals can spread the disease to others."

That scenario is playing out in the fact that malaria is no longer only a disease of sub-Saharan Africa and southern Asia. Increasing numbers of people emigrating from countries where malaria is endemic have resulted in a higher incidence in Europe and the Middle East. The proportion of imported malaria cases has increased during the last few years from 14% to 86% in more recent studies. On pooling the reports, nearly 43% of malaria cases registered in key European centers occurred in non-nationals. The rates of malaria are much higher in settled immigrants who travel to visit friends and relatives in their country of origin. They can account for up to 70% of the cases in several reports and this increase highlights the need for better diagnostic tools in both non-endemic and endemic countries. 

While not a new concept, molecular testing has traditionally been a complex process requiring fully-equipped laboratories and highly trained testing personnel. The breakthrough of  illumi gene Malaria by Meridian Bioscience is that it can be deployed in the field laboratory, where malarial infection is the highest and low load detection most challenging to diagnose and treat.  illumi gene Malaria is user-friendly, doesn't require special training or capital investment, yields results in under one hour and the testing materials can be stored at room temperature.

"This is a major step forward in the fight to bring better care to those infected with malaria and to stop its spread," said John A. Kraeutler, Chief Executive Officer and Chairman of the Board of Meridian Bioscience.

The availability of the field laboratory-deployable and user-friendly,  illumi gene Malaria, will enhance rather than replace existing testing protocols. It will join rapid diagnostic tests (RDTs) and microscopy to create a web of detection protocols that will help direct treatment where it is needed most.

"Malaria is a devastating disease and we are proud to work with all the talented and dedicated individuals around the world in the fight to eliminate it," said Kraeutler. 

illumi gene Malaria will be distributed in the European, Middle Eastern and African regions by Meridian Bioscience Europe and in additional international markets by the Company's global distribution network. It is the tenth assay now available on our  illumi gene platform that is in use in nearly 1,500 institutions around the world.

1 - Meridian news release, "New Malaria Test, illumigene Malaria, Sets a New Gold Standard for Diagnosis", 1.26.16
2 - World Health Organization: 10 facts on malaria (http://www.who.int/features/factfiles/malaria/en/) Updated December 2016
3 - ibid
4 - ibid
5 - ibid
6 - The World Health Organization, Global Technical Strategy for Malaria: 2016-2030

About  Meridian Bioscience illumigene Malaria & LAMP Technology

  • illumi gene Malaria is a diagnostic test for malaria developed by Meridian Bioscience. It is a molecular test that uses Loop-Mediated Isothermal Amplification (LAMP) technology to amplify DNA and detect the presence of the Malaria parasite.
  • LAMP (Loop Mediated Isothermal Amplification) is Molecular detection technology which targets DNA and uses premeasured and self-contained reagents.  Unlike current PCR testing, it does not require temperature cycling. LAMP incubates, detects and reports at a single temperature, allowing for faster results.  illumi gene testing kits can be stored under ambient conditions, while current molecular methods require cold storage.
  • illumi gene technology is simple, accurate and easy to use which means that no specialist technical expertise is needed to perform the test. Results are available in under an hour.
  • LAMP-based  illumi gene tests are already used to diagnose infectious diseases including C. difficile, whooping cough and Herpes Simplex Virus, where they have proved highly accurate.
  • illumi gene tests have been approved and used in other diseases for over 5 years.
  • The benefits of  illumi gene Malaria are highlighted on the microsite: www.molecularendsmalaria.com.

About Meridian Bioscience, Inc 
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company's shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

For Investor Relations, contact:     
513-271-3700
John A. Kraeutler, Chief Executive Officer

For all other inquiries, contact:
513-403-7222
Joe Shields




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Meridian Bioscience, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Early Warning Report23.5.2018 20:05Pressmeddelande

VANCOUVER, British Columbia, May 23, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) announces that pursuant to a warrant exercise, it has acquired for a purchase price of C$803,571, direct ownership of 5,357,142 common shares (the "Shares") of Prospero Silver Corp. ("Prospero"), of 510 West Georgia Street, Suite 1800, Vancouver, BC V6B 0M3, at a price of C$0.15 per Share. Immediately following this transaction, Fortuna owned 10,714,284 common shares of Prospero, representing 22.74% of the issued and outstanding common shares of Prospero. Immediately prior to the transaction, Fortuna owned 5,357,142 common shares and 5,357,142 common share purchase warrants. The Shares were acquired by Fortuna for investment purposes, and depending on market and other conditions, it may from time to time in the future increase or decrease its ownership, control or direction over securities of Prospero through market transactions, private agreements, or otherwise. Fortuna has fil

LeoVegas continues to invest for the future with the launch of a new front-end platform23.5.2018 15:54Pressmeddelande

The front-end platform is what the customers meet when entering LeoVegas.com. The technology creates new and improved opportunities for LeoVegas to offer the best, fastest and most innovative mobile gaming experience. "We are investing further in state-of-the-art technology in order to continuously develop the customer experience and to create conditions for strong growth. Together with our back-end platform, Rhino, we are maintaining our technological lead in the industry and continue to be the leading GameTech company by working with world class technology," comments Gustaf Hagman, Group CEO of LeoVegas. The platform offers wide range of benefits which demonstrate LeoVegas' position as the leading GameTech company: The platform enables faster loading times and thus a better customer experience. The platform opens significantly greater opportunities for improved Search Engine Optimisation (SEO). The value of improved SEO is that customers will be directed straight to Leovegas.com via

LeoVegas fortsätter att investera för framtiden med lansering av ny front-end plattform23.5.2018 15:54Pressmeddelande

Front-end plattformen är det som kunderna möts av på LeoVegas.com. Tekniken skapar nya och förbättrade möjligheter för LeoVegas att fortsätta erbjuda den bästa, snabbaste och mest innovativa spelupplevelsen på mobilen. "Vi fortsätter att investera i den senaste tekniken för att ständigt utveckla kundupplevelsen och skapa förutsättningar för stark tillväxt. Tillsammans med vår back-end plattform, Rhino, behåller vi vårt teknikförsprång i branschen och fortsätter att vara det ledande GameTech bolaget genom att arbeta med teknik i världsklass", säger Gustaf Hagman, CEO LeoVegas. Fördelarna med den nya plattformen är många och visar på att LeoVegas är det ledande GameTech bolaget: Snabbare laddning och därmed en bättre upplevelse för kunden. Möjligheter till ett förbättrat SEO-arbete ökar markant. Värdet av förbättrad SEO är att kunderna kommer hitta direkt till Leovegas.com via sökmotorer istället för att gå via tredje part, så kallade affiliate-sajter. LeoVegas har en förväntan om att ök

GaN Systems to Showcase Innovative GaN Power Technologies and Customer Solutions at PCIM Europe 201823.5.2018 15:00Pressmeddelande

Record-setting GaN transistors and an array of new products, design tools, and reference designs that make it easier to develop ground-breaking power systems will be displayed OTTAWA, May 23, 2018 (GLOBE NEWSWIRE) -- GaN Systems, the global leader in GaN (gallium nitride) power semiconductors, today announced that it will be exhibiting the company's new products and design tools and presenting customer demonstrations at PCIM Europe 2018 (Power Conversion and Intelligent Motion), Booth 511 in Hall 9 (9-511) from June 5-6, 2018 in Nuremberg, Germany. At PCIM Europe, one of the leading exhibitions for power electronics and its applications, attendees to the GaN Systems booth will learn about new products, the numerous IC companies that have collaborated with GaN Systems, and a vast array of customer implementations spanning the consumer, data center, industrial, and automotive market segments. Also, GaN Systems' subject matter experts will be speaking at four sessions over the course of t

Addiko Bank Implements Digital Banking Solutions on Appian23.5.2018 13:30Pressmeddelande

Digital Lending and Trade Finance applications cut customer wait times in half RESTON, Va., BELGRADE, Serbia and LJUBLJANA, Slovenia, May 23, 2018 (GLOBE NEWSWIRE) -- Appian (Nasdaq:APPN) and Addiko Bank, an international financial group headquartered in Vienna, Austria, today announced that the bank has deployed two new digital banking applications on Appian's low code application platform. The applications cover Lending and Trade Finance processes across Addiko's Corporate and Small Medium Enterprise (SME) customers. The applications have reduced customer wait times by as much as 50% by cutting "time to yes" for simple loans down from one week to just three days. Addiko Bank is the only financial group primarily focused on markets in the South Eastern Europe region (SEE), servicing more than 1 million customers. With these Appian deployments, Addiko Bank is the first bank within the SEE region to provide such a digital banking platform to customers in Slovenia and Serbia. Addiko is a

GMO Internet Group Offers GMO miner, The World's First Mining Machine Equipped with Mining Chips Using a Cutting-Edge 7 nm Process Technology: information session on Wednesday, June 623.5.2018 13:03Pressmeddelande

TOKYO, May 23, 2018 (GLOBE NEWSWIRE) -- Tokyo, Japan - May 23, 2018 - GMO Internet Group (https://www.gmo.jp/en/ ) will launch GMO miner (product name: GMO miner B2), which is our own high-performance computer for mining (mining machine), on Wednesday, June 6, 2018. We will mass-produce the world's first mining machine equipped with a cutting-edge 7 nm* process based semiconductor chip (7 nm mining chip; "GMO 72b"), which will be shipped at the end of October 2018. As a result, an information session for potential customers considering the purchase of GMO miner will be held on Wednesday, June 6 in Shibuya, Tokyo, and we will explain the details of GMO miner, such as price and performance. *nm: nanometer. 1/1 billion meters. 1/1 million millimeters. Selling "GMO miner" Cryptocurrency mining requires high-performance mining machines enabling highly sophisticated and intensive computation. Accordingly, GMO Internet Group has been working on research and development of a cutting-edge 7 nm

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum